Astex Pharmaceuticals has initiated phase 2, open-label, single-arm, clinical trials evaluating SGI-110 in the treatment of advanced hepatocellular carcinoma (HCC) patients who failed prior treatment ...
Kenilworth-based Merck announced on Monday an exclusive worldwide research collaboration and license agreement. “At Merck we continue to pursue new regimens designed to extend the benefits of highly ...
CAMBRIDGE, Mass., June 25, 2020 (GLOBE NEWSWIRE) -- Immuneering Corporation today announced a collaboration between its neuroscience division, known as Alleo Labs, and Astex Pharmaceuticals (UK), a ...
ASTX528 is a novel small molecule CBP/p300 HAT domain inhibitor with potent in vivo activity and a favourable safety profile in preclinical species that was discovered by Astex using its proprietary ...
Partnership aims to identify small molecule candidates’ activity towards tumor suppressor protein. Astex Pharmaceuticals, and MSD (Merck), have revealed a worldwide research collaboration, intending ...
GlaxoSmithKline (GSK) has inked a deal with Astex Therapeutics to discover, develop, and commercialize compounds directed against multiple targets for £20 million (about $33 million) up front. Astex ...
The University of Texas MD Anderson Cancer Center and Astex Pharmaceuticals, Inc., a wholly owned subsidiary of Otsuka Pharmaceutical Co. Ltd., based in Tokyo, Japan, today announce a strategic ...
NEW YORK (AP) -- Shares of Astex Pharmaceuticals Inc. rose Wednesday after the company said it received a $5.4 million payment from its partner Johnson & Johnson. THE SPARK: Astex said J&J's Janssen ...
In the latest buyout of what’s been a busy M&A week, Japanese drug maker Otsuka inked an $886 million pact on Thursday to snag U.S. cancer treatment maker Astex (NASDAQ:ASTX). The deal will allow ...
PLEASANTON, Calif. & HOUSTON--(BUSINESS WIRE)--Astex Pharmaceuticals, Inc., a wholly owned subsidiary of Otsuka Pharmaceutical Co. Ltd., based in Tokyo, Japan, and The University of Texas MD Anderson ...
PLEASANTON, Calif.--(BUSINESS WIRE)--Astex Pharmaceuticals, Inc., a wholly owned subsidiary of Otsuka Pharmaceutical Co., Ltd., based in Tokyo, Japan, announces that the US Food & Drug Administration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results